07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

IMA950: Phase I data

immatics reported data from an open-label, U.K. Phase I trial in 45 patients with newly diagnosed glioblastoma showing that IMA950 plus standard of care (SOC) surgery and concomitant or adjuvant chemotherapy with temozolomide met the...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

MVA-EBNA/LMP2 vaccine: Phase Ib started

Cancer Research UK said its Drug Development Office ( DDO) began a U.K. Phase Ib trial to evaluate 3 doses of intradermal MVA-EBNA/LMP2 vaccine every 3 weeks followed by another dose 12 weeks later in...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

DI-B4: Phase I started

Cancer Research U.K. (London, U.K.) said its Drug Development Office ( DDO) began an open-label, dose-escalation, U.K. Phase I trial to evaluate IV DI-B4 weekly for 4 weeks in about 40 patients with relapsed or...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Eli Lilly, Cancer Research U.K. cancer news

On Dec. 17, 2013, Eli Lilly joined the Experimental Cancer Medicine Centres (ECMC) Combination Alliance, a joint initiative between Cancer Research U.K.'s Drug Development Office ( DDO), the ECMC and pharma companies. Lilly will provide...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

AstraZeneca, Cancer Research U.K. deal

On Dec. 20, 2013, Cancer Research U.K.'s Drug Development Office ( DDO) and commercial subsidiary, Cancer Research Technology (CRT) Ltd., agreed to a clinical development partnership with AstraZeneca to develop the pharma's AZD2098 for...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

AZD3965: Phase I started

Cancer Research U.K. began a 2-part, open-label, dose-escalation, U.K. Phase I trial to evaluate 5, 10, 20 and 30 mg oral AZD3965 given once or twice daily in 28-day cycles for up to 6 cycles...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

AZD0424: Phase I started

Cancer Research U.K. (London, U.K) began an open-label, U.K. Phase I trial of once-daily oral AZD0424 from AstraZeneca for 28 days in about 96 patients. The dose-escalation Phase Ia portion will evaluate AZD0424 alone and...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Lorus, Cancer Research U.K. deal

Cancer Research U.K.'s Drug Development Office ( DDO) and commercial subsidiary Cancer Research Technology (CRT) Ltd. agreed to a clinical development partnership with Lorus to develop the biotech's proinflammatory cytokine interleukin-17E (IL-17E) cancer compound. Under...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Clinical News

AZD8931: Phase Ib/IIa started

Cancer Research UK (London, U.K) said Oxford University began a dose-escalation, open-label, U.K. Phase Ib/IIa trial to compare AZD8931 plus Xelox chemotherapy (a combination of oral Xeloda capecitabine and IV oxaliplatin) vs. Xelox alone...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

AZD4547: Phase Ib/IIa started

Cancer Research UK (London, U.K) began a dose-finding, U.K. Phase Ib/IIa trial to evaluate AstraZeneca's AZD4547 plus cisplatin and capecitabine. The Phase Ib portion of the trial will enroll about 18 patients with solid tumors...